Initiator Pharma A/S announced that the first subject has been dosed with the drug substance IP2015 in the IPTN2021 program clinical Phase I study in healthy subjects challenged with pain inducing ingredient (capsaicin). The dosing in Initiator Pharma's Phase I study has started as planned and according to the Authority and Ethics Committee approved study protocol. The study is a randomised, double#blind, placebo#controlled study to investigate the pharmacodynamic effects of IP2015 in 24 healthy male subjects using the intradermal capsaicin model.

The study is carried out in collaboration with MAC Clinical Research, UK, as a single site study. Pending current and future Covid-19 restrictions, first results are expected sometimes during the second quarter 2022.